Ocrevus Zunovo (ocrelizumab and hyaluronidase)

**Product type:** Human Prescription Drug

**Active ingredient:** HYALURONIDASE (HUMAN RECOMBINANT); OCRELIZUMAB

**Strength:** 23000; 920 U/23mL; mg/23mL

**Dosage form:** Injection, Solution

**Route:** Subcutaneous

**Labeler:** Genentech, Inc.

**Marketing category:** BLA (BLA761371)

**Pharmacologic class:** Antibodies, Monoclonal [CS], Antibodies, Monoclonal, Humanized [CS], CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC], Endoglycosidase [EPC], Glycoside Hydrolases [CS]